Real-world data showed zanubrutinib was associated with longer time to next treatment and improved overall survival vs acalabrutinib in treatment-naive CLL.
Assessing Real-World Outcomes With BTK Inhibitor Monotherapy in Treatment-Naive CLL
Advertisement
Advertisement
Trending on OncLive
1
Targeted Therapies, ADCs, and Oral SERD Combos Expand Treatment Possibilities Across Breast Cancer Settings
2
Head and Neck Oncologists Highlight Practice-Informing Research From ASCO 2026
3
Generic Ga-68 PSMA-11 Radiodiagnostic Nets FDA Approval in Prostate Cancer
4
Dr Galsky on the Current Roles of Biomarkers in Bladder Cancer
5